Magnetic resonance imaging findings and neurodevelopmental outcomes in neonates with urea-cycle defects

Anna Catherine Gunz¹
Karen Choong²
Murray Potter³
Elka Miller⁴
¹Division of Critical Care, Department of Pediatrics, University of Ottawa, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; ²Department of Pediatrics, ³Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; ⁴Diagnostic Imaging Department, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada

Abstract: The urea-cycle functions to facilitate ammonia excretion, a disruption of which results in the accumulation of toxic metabolites. The neurological outcome of neonatal-onset urea-cycle defects (UCDs) is poor, and there are no good predictors of prognosis beyond ammonia levels at presentation. The role of neuroimaging in the prognosis of neonatal-onset UCDs is unclear. We describe the magnetic resonance imaging (MRI) findings of two patients with neonatal-onset UCDs (argininosuccinic aciduria and citrullinemia) at presentation and at 2-year follow-up, and present a review of the literature on neuroimaging in this age-group. We observed two potentially significant distinct patterns of cerebral involvement on MRI: (1) a central and focal pattern of involvement limited to the basal ganglia, perirolandic regions, and internal capsule; and (2) diffuse involvement of the cerebral cortex, internal capsule, basal ganglia, and variably thalami and brain stem. Patients with more diffuse findings tended to have higher serum glutamine peaks and worse neurological outcomes, while those with central involvement, aggressive acute management, and early liver transplantation tended to have better outcomes. We propose that MRI imaging of the brain may have prognostic value following presentation with neonatal UCDs, particularly in identifying patients at risk for poor outcome. The role and timing of follow-up neuroimaging is currently unclear. Further collaborative studies are necessary to evaluate whether patterns of MRI findings vary with specific UCD subtypes, and are predictive of clinical outcomes in neonatal UCDs.

Keywords: hyperammonemia, amino acid metabolism, inborn error, metabolism, inborn errors, infant, newborn, magnetic resonance imaging

Introduction

Urea-cycle defects (UCDs) result in hyperammonemia and the accumulation of glutamine and various toxic metabolites. Neonatal-onset UCDs are associated with poor neurodevelopmental outcome, often resulting in cerebral palsy and developmental delay.¹–³ Left untreated, these disorders result in progressive seizures, coma, and death. The use of magnetic resonance imaging (MRI) is increasingly reported in neonatal hyperammonemia;⁴–⁷ however, the association with neurological outcome is unclear.

We present two cases of neonatal-onset UCD, their brain MRI findings, and neurodevelopmental outcome at 2 years. We reviewed the literature and summarize the reported patterns of MRI findings in this population, and hypothesize their significance in relation to subtypes of UCD, biochemical markers, and neurodevelopmental outcome.

Case 1: argininosuccinic aciduria

A full-term female infant presented on her second day of life (DOL) with seizures, hypovolemic shock, multi-organ system dysfunction, peak serum ammonia in the acute phase...
of 1,092 µmol/L (normal <80 µmol/L), and peak glutamine in the acute phase of 1,728 µmol/L (normal 376–709 µmol/L, Table 1). Ammonia-lowering agents (sodium benzoate, sodium phenylacetate, and L-arginine) were promptly initiated; she had approximately 12 hours of hemodialysis. Her ammonia normalized within 36 hours. Quantitative plasma amino acid analysis confirmed a diagnosis of the UCD, argininosuccinic aciduria (argininosuccinic acid 853 µmol/L, citrulline 292 µmol/L [normal 10–24 µmol/L], urine argininosuccinic acid 58,617 µmol/L). At 20 months, she was noted to have moderate language and motor delays (Table 2).

MRI was performed on DOL 8 (Figure 1A and B). T1- and T2-weighted images showed increased signal intensity of the globus pallidus, caudate nucleus, internal capsule, and bifrontal corona radiata, extending into the perirolandic regions. There was no restricted diffusion. Follow-up imaging at 25 months (Table 3) revealed residual signal change of the caudate nucleus and globus pallidus, with globus pallidus volume loss (Figure 1C).

**Case 2: citrullinemia**

This full-term female infant presented on DOL 7 with seizures, peak serum ammonia of 1,345 µmol/L, and peak serum glutamine of 3,055 µmol/L (Table 1). Ammonia-lowering agents were initiated; she had 4 hours of hemodialysis. Her ammonia level normalized within 24 hours. The quantitative amino acid profile yielded a diagnosis of citrullinemia (citrulline 4,074 µmol/L, ornithine 25 µmol/L [normal 48–211 µmol/L], arginine 62 µmol/L [normal 6–140 µmol/L], no urine argininosuccinic acid). At 27 months, she displayed mild motor and language delays, microcephaly and failure to thrive (less than third percentile for head circumference, height, and weight; Table 2).

MRI on DOL 11 (Figure 2A and B) demonstrated diffuse restricted diffusion with predominance posteriorly, sparing the superior frontal lobe and parts of the temporal lobe. There was involvement of the globus pallidus, internal capsule, corpus callosum, thalami, and cerebral peduncles. At 24 months of age, repeat MRI (Table 3) showed increased signal of the periventricular white matter with associated posterior white-matter volume loss and ventricular enlargement (Figure 2C).

**Discussion**

**Patterns of brain MRI findings and urea-cycle defects**

A review of the literature found four case reports of brain MRIs of eight neonates after acute presentation with neonatal-onset hyperammonemia, summarized in Table 1. Based on these cases, we interpreted two patterns of cerebral

**Table 1** Location of cerebral involvement, as indicated by magnetic resonance imaging (MRI), of cases of neonatal-onset urea-cycle defects in the subacute phase of recovery after presentation, as well as timing of presentation and MRI, peak serum ammonia, and glutamine levels

| Diagnosis       | Age at diagnosis | Age at MRI | Peak ammonia a (µmol/L) | Peak glutamine a (µmol/L) | Pattern of cerebral involvement | Perirolandic | Insula |
|-----------------|------------------|------------|-------------------------|---------------------------|---------------------------------|--------------|--------|
| Patient 1 ASA   | DOL 2            | DOL 8      | 1,092                   | 1,728                     | Central                         | +            | +      |
| Patient 2       | DOL 7            | DOL 11     | 1,345                   | 3,055                     | Diffuse                         | +            | +      |
| Patient 3 a     | DOL 2            | 2 weeks    | 978                     | 1,710                     | Central                         | +            | +      |
| Patient 4 a     | DOL 4            | 2 weeks    | 1,420                   | Central                   | +                                | +            |        |
| Patient 5 a     | DOL 2            | 2 weeks    | 1,700                   | Central                   | +                                | +            |        |
| Patient 6 a     | DOL 5            | DOL 8      | 2,083                   | Diffuse                   | +                                | +            |        |
| Patient 7 a     | DOL 2            | DOL 12     | 952                     | 6,491                     | Diffuse                         | +            | +      |
| Patient 8 a     | DOL 2            | DOL 5      | 3,035                   | 2,883                     | Diffuse                         | +            | +      |
| Patient 9 a     | DOL 1            | DOL 8      | 2,652                   | 3,308                     | Diffuse                         | +            | +      |
| Patient 10 a    | DOL 2            | DOL 8      | 2,196                   | 3,809                     | Diffuse                         | +            | +      |
| Patient 11 a    | DOL 1 b          | DOL 5      | 2,684                   | 3,398                     | Central                         | +            | +      |

**Notes:** aPeak concentration during initial acute presentation; brecognized within 8 hours and corrected rapidly in 24 hours (patients 1, 2, and 3 recognized belatedly). Patient 1 and 2 are Case 1 and 2 of this study, respectively.

**Abbreviations:** ASA, argininosuccinic aciduria; CPS I, carbamoyl phosphate synthetase I deficiency; CN, caudate nucleus; GB, globus pallidus; OTCD, ornithine transcarbamylase deficiency; DOL, day of life; MOD, multiorgan dysfunction; N/A, not applicable.
involvement on MRI: diffuse and central/focal. The “diffuse” pattern consists of extensive involvement of the cerebral cortex (particularly the posterior cortices excluding the superior frontal and medial temporal lobes), basal ganglia, and in some cases, thalami and brain stem; the “central” pattern consists of signal changes limited to the basal ganglia, periolandic region, and internal capsule.

The diffuse pattern of cerebral involvement was more commonly associated with high peak serum glutamine levels (>2,800 µmol/L) than serum ammonia levels during the acute phase of presentation. In addition, we note that the diffuse pattern of cerebral involvement was common to cases of citrullinemia. While our patient with argininosuccinic aciduria presented with multiorgan dysfunction, which may have contributed to the pattern of cerebral involvement noted on MRI, the pattern of involvement was similar to other patients with UCD who did not present with multiorgan dysfunction. There was insufficient information provided in the literature to demonstrate a relationship between duration of hyperammonemia and patterns of cerebral involvement.

**Neuropathophysiology of urea-cycle defects and findings on neuroimaging**

Authors have described a correlation between severity of outcome and duration and/or peak concentration of ammonia. Current hypotheses suggest the direct effect of hyperammonemia on the brain causes more injury than cerebral edema from its osmotically active toxic metabolite, glutamine, alone. In order to detoxify ammonia, glutamine synthetase (GS) catalyzes the condensation of ammonia and glutamate to form glutamine in astrocytes. However, if the GS-enzyme pathway becomes saturated, ammonia will accumulate. Elevated cerebral ammonia has a number of neurophysiological effects, including increased cerebral edema from impaired glucose oxidation and subsequent lactate accumulation, loss of cerebral autoregulation, effects on neurotransmitters, synaptic transmission, nitric oxide synthesis, and stimulation of N-methyl-D-aspartate receptors, which may downregulate GS. In our study, the demonstrated association between more diffuse cerebral involvement and high glutamine peaks builds upon the findings of Bireley et al, and seems contrary to what is understood about the pathogenesis of hyperammonemia.

The bulk of the literature dedicated to understanding the neuropathogenesis of UCDs focuses on the neurotoxic effects of glutamine and hyperammonemia. However, there may be additional neurotoxic effects of specific metabolites of different subtypes of UCD, such as with arginase deficiency and citrullinemia. This may contribute to the diffuse pattern of

| Basal ganglia | Internal capsule | Temporal | Parietal-occipital | Frontal | Thalami | Corpus callosum | Brain stem | Restricted areas in diffusion-weighted imaging |
|--------------|-----------------|---------|-------------------|--------|--------|-----------------|-----------|-----------------------------------------------|
| + (GB&CN)    |                  |         |                   | +      | +      | +               | +         | None                                          |
| + (GB&CN)    | +               |         |                   | +      | +      | +               | +         | Diffuse, sparing superior frontal and parts of temporal lobes |
| + (GB)       | +               |         |                   | +      | +      | +               | +         | Unknown                                       |
| + (GB&CN)    |                  |         |                   | +      | +      | +               | +         | No MODs                                       |
| + (GB)       | +               | +      |                   | +      | +      | +               | +         | Diffuse, corresponds with T2 signal changes   |
| + (GB&CN)    |                  |         |                   | +      | +      | +               | +         | Diffuse, as described, including optic radiata, cerebral peduncle, scattered through cortex (particularly posterior) |
| + (GB)       |                  |         |                   | +      | +      | +               | +         | Diffuse, as described                        |
| + (GB&CN)    | +               |         |                   | +      | +      | +               | +         | Diffuse, as described                        |
| + (GB)       |                  |         |                   | +      | +      | +               | +         | Limited, as described                        |
Table 2 Neurodevelopmental and long-term outcome of patients with a diffuse or central pattern of cerebral involvement, as well as peak serum ammonia and glutamine levels after acute presentation by subtype of urea-cycle defect

| Diagnosis      | Peak ammonia* (μmol/L) | Peak glutamine* (μmol/L) | Pattern of cerebral involvement (acute phase) | Further episodes of hyperammonemia prior to follow-up |
|----------------|-------------------------|--------------------------|-----------------------------------------------|------------------------------------------------------|
| Patient 1     | ASA                     | 1,092                    | 1,728                                         | Yes**                                                |
| Patient 2     | Citrullinemia           | 1,345                    | 3,055                                         | Diffuse                                              |
| Patient 3     | CPS I                   | 978                      | 1,710                                         | Diffuse                                              |
| Patient 4     | OTCD                    | 1,420                    | Localized                                     | Yes                                                  |
| Patient 5     | CPS I                   | 1,700                    | 1,268                                         | Localized                                            |
| Patient 6     | Citrullinemia           | 2,083                    | 3,067                                         | Diffuse                                              |
| Patient 7     | OTCD                    | 952                      | 6,491                                         | Diffuse                                              |
| Patient 8     | OTCD                    | 3,035                    | 2,883                                         | Diffuse                                              |
| Patient 9     | OTCD                    | 2,652                    | 3,308                                         | Diffuse                                              |
| Patient 10    | Citrullinemia           | 2,196                    | 3,809                                         | Diffuse                                              |
| Patient 11    | OTCD                    | 2,684                    | 3,398                                         | Localized                                            |

Notes: *Peak concentration during initial acute presentation; **two severe episodes at 18 and 26 months old, respectively, and 1 minor episode at 28 months old; ***where applicable. Patient 1 and 2 are Case 1 and 2 of this study, respectively.

Abbreviations: ASA, argininosuccinic aciduria; CPS I, carbamoyl phosphate synthetase I deficiency; DOL, day of life; OTCD, ornithine transcarbamylase deficiency; WOLS, withdrawal of life support.

Neuroimaging and neurodevelopmental outcome

The neurodevelopmental outcomes of patients were graded according to the schema introduced by Bireley et al\(^6\) (Table 2). Patients with mild outcomes had transient symptomatology during periods of hyperammonemia that completely resolved. Those with moderate outcomes had persistent neurocognitive delays or neurological abnormalities. Patients with severe outcomes had profound neurocognitive delays or severe spastic quadriplegia. Generally, patients with more extensive cortical involvement had more severe neurodevelopmental outcomes (Table 2). An exception was our citrullinemia case (patient 2). In contrast, children with central cerebral involvement had variable neurodevelopmental outcomes. The subtype of UCD was not predictive of neurodevelopmental outcome.

That more extensive cerebral involvement noted on MRI translates into more severe neurodevelopmental outcome follows. However, the fact that not all patients with diffuse involvement had severe outcomes (ie, patient 2), and that patients with a central pattern of cerebral involvement or similar subtypes of UCD had variable outcomes, reflects the complexity of the neuropathophysiology of these disorders. Important contributing factors may include cumulative patient-specific factors, such as the duration of hyperammonemia on presentation, chronic exposure to mild hyperammonemia, number of subsequent episodes of severe hyperammonemia (patient 2 had no subsequent episodes), and exposure to other toxic UCD metabolites.

Early and aggressive management of patients with neonatal-onset UCD, regardless of subtype, may modify the neurocognitive outcome. The patients with better neurological outcomes (patients 4\(^4\) and 11\(^5\)), had liver transplants at an early age, early and aggressive management (patient 4\(^4\)), or no repeated episodes of hyperammonemia (patients 2 and 11\(^6\)). The patients with more severe neurodevelopmental outcomes (patients 3\(^4\) and 5\(^4\)) had repeated episodes of hyperammonemia and/or transplantation at a later age.

Patients with brain-stem and thalamic involvement tended to have worse neurodevelopmental outcomes, with the exception of patient 2. While Bireley et al\(^6\) hypothesized that thalamic injury may be partially caused by secondary anoxic insult from hemodynamic instability, it may simply represent more severe cerebral disease (our patient with thalamic involvement remained hemodynamically stable). In contrast to Bireley et al\(^6\) findings, restricted diffusion was not consistently associated with worse outcome.

Pattern of cerebral involvement demonstrated in follow-up imaging

The degree of signal resolution and development of cerebral volume loss demonstrated by follow-up MRIs...
Neurodevelopmental sequelae | Neurodevelopmental outcome | Age at death*** | Cause of death*** | Age at liver transplant***
--- | --- | --- | --- | ---
Moderate | Moderate language and motor delay | | | |
Moderate | Microcephaly, failure to thrive, mild language and motor delay | | | |
Severe | Truncal hypotonia, appendicular hypertonia, choreoathetosis, global neurodevelopmental delay | 8 months | | |
Moderate | Nonoral food intake, age-appropriate development | 6 weeks | | |
Moderate | Moderate neurodevelopmental delays | 7 months | | |
Severe | 4 months old: microcephaly, severe neurodevelopmental delay, hypotonia, head lag, hyperreflexia | | | |
Severe | DOL 89: microcephaly, no head control, suck and swallow uncontrolled, hyperreflexia, clonus bilaterally | | | |
Severe | “Severe quadriparetic cerebral palsy with minimal development” | 15 months | Unknown | |
Severe | “Neurological devastation” | DOL 15 | WOLS | |
Severe | “Severely depressed neurological function” | DOL 20 | WOLS | |
Moderate | Hypotonia and mild motor delays at 1 year old | 11 weeks | | |

varied (Table 3). The consistent findings of signal changes and volume loss in the basal ganglia and posterior cerebral cortex (including parieto-occipital encephalomalacia in severe cases) reinforce the importance of these structures in the pathogenesis of this disease.

From the information presented, it is difficult to demonstrate a clear relationship between the pattern of cerebral involvement noted on MRI after acute presentation and long-term follow-up. This is due to the variability in the timing and indication of follow-up imaging in this series, as well as the small number of patients with each subtype of UCD who underwent later imaging. In addition, it is unclear to what extent the pattern of cerebral involvement seen in later imaging reflects subsequent episodes of hyperammonemia. For example, the later imaging of patient 8 was the only follow-up imaging that demonstrated restricted diffusion. However, this MRI was done 2 days after the patient presented with an episode of hyperammonemia, and thus likely reflects this acute process. Overall, we question the clinical utility of follow-up imaging, as it may not change clinical management when there are no further episodes of hyperammonemia.

Limitations of this review include the small sample size, which reflects the rarity of this disease, and lack of access to full case images and developmental assessments from the literature. In addition, for each case, the number of days that an MRI was done after acute presentation varied from 3 days to 2 weeks, which may affect the degree of diffusivity noted on the respective diffusion-weighted imaging.13,14

For example, the later imaging of patient 8 was the only follow-up imaging that demonstrated restricted diffusion. However, this MRI was done 2 days after the patient presented with an episode of hyperammonemia, and thus likely reflects this acute process. Overall, we question the clinical utility of follow-up imaging, as it may not change clinical management when there are no further episodes of hyperammonemia.

Limitations of this review include the small sample size, which reflects the rarity of this disease, and lack of access to full case images and developmental assessments from the literature. In addition, for each case, the number of days that an MRI was done after acute presentation varied from 3 days to 2 weeks, which may affect the degree of diffusivity noted on the respective diffusion-weighted imaging.13,14

**Figure 1** Axial T1- (A) and T2-weighted magnetic resonance images (B) of case 1 show increased signal intensity of the internal capsule, globus pallidus (arrows) and caudate nucleus (stars), bifrontal corona radiata, extending into the perirolandic regions (not shown). Axial T2-weighted magnetic resonance image (C) of case 1 done at follow-up at 25 months reveals residual signal change of the caudate nucleus (stars) and globus pallidus, with decreased size of the globus pallidus (arrows).
Table 3 Location of cerebral involvement demonstrated by follow-up magnetic resonance imaging (MRI) by subtype of urea-cycle defect, age, and imaging indication, also including number of subsequent episodes of hyperammonemia between presentation and follow-up imaging.

| Diagnosis | Further episodes of hyperammonemia prior to follow-up | Indication for follow-up MRI | Age at follow-up MRI | Volume loss | Basal ganglia | Thalami | Parietooccipital leukomalacia | Other |
|-----------|--------------------------------------------------------|-----------------------------|---------------------|-------------|--------------|---------|---------------------------|-------|
| Patient 1 ASA Yes* | Routine follow-up | 25 months | GP only | T2 increased signal GP and CN | | | | |
| Patient 2 Citrullinemia | No | Routine follow-up | 24 months | Diffuse posterior | T2 increased signal GP and CN | T2 increased signal Insula | | |
| Patient 3 CPS I | Yes | After 2 significant episodes of hyperammonemia | 7 months | Diffuse atrophy; VL mostly BG | T2 prolongation GP and CN; T1 shortening of putamen | | | | |
| Patient 6 Citrullinemia | No | Unknown | 4 months | Extensive | | | | Subcortical cysts (especially occipital); ulegyric changes |
| Patient 7 OTCD | Unknown | Unknown | 3 months | Global | | | | Bilateral T1 high signal cerebral white matter |
| Patient 8 OTCD | Yes | 2 days after hyperammonemic episode | 11 months | Moderate | | | Restricted diffusion | Restricted diffusion temporal and occipital |
| Patient 11 OTCD | No | Unknown | 6 months | Moderate | | | | Resolution of previously restricted diffusion |

Notes: *Peak concentration during initial acute presentation; **recognized within 8 hours and corrected rapidly in 24 hours (patients 1, 2, and 3 recognized belatedly); Patient 1 and 2 are Case 1 and 2 of this study, respectively. 
Abbreviations: ASA, argininosuccinic aciduria; BG, basal ganglia; CPS I, carbamoyl phosphate synthetase I deficiency; CN, caudate nucleus; DOL, day of life; GP, globus pallidus; OTCD, ornithine transcarbamylase deficiency; VL, volume loss.
Conclusion

For clinicians involved in the acute management of neonates presenting with UCDs, prognostication is extremely important, as some parents will elect to withdraw life-sustaining therapy if the projected neurodevelopmental outcome is devastating. We hypothesize that the pattern of cerebral involvement seen in the subacute phase of recovery from hyperammonemia on MRI, as well as early biomarkers such as glutamine, may have a role in predicting neurodevelopmental outcome in these children. If MRI reveals a central pattern of involvement, strict and aggressive management and early hepatic transplantation may help preserve neurological function. However, given the rarity of this disease, scarcity of published case reports, and inconsistency in neurodevelopmental reporting and follow-up presented in the literature, clinical decision-making based on neuroimaging results alone should be done with caution. Large clinical trials are necessary to delineate more clearly the predictive value of neuroimaging after acute presentation, as well as the relative importance of aggressive therapeutics, in the long-term neurodevelopmental outcome of these children. The clinical utility of follow-up imaging is unclear.

Disclosure

The authors have no financial or personal relations that may provide a conflict of interest.

References

1. Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr. 2003;162(6):410–416.
2. Uchino T, Endo F, Matsuda I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis. 1998;21 Suppl 1:151–159.
3. Eans GM. Neurologic damage and neurocognitive dysfunction in urea cycle disorders. Semin Pediatr Neurol. 2008;15(3):132–139.
4. Takahashi I, Barkovich AJ, Cheng SF, et al. Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders. AJNR Am J Neuroradiol. 2003;24(6):1184–1187.
5. Majoe CB, Mourmans JM, Akkerman EM, Duran M, Poll-The BT. Neonatal citrullinemia: comparison of conventional MR, diffusion-weighted, and diffusion tensor findings. AJNR Am J Neuroradiol. 2004;25(1):32–35.
6. Bireley WR, Van Hove JLK, Gallagher RC, Fenton LZ. Urea cycle disorders: brain MRI and neurological outcome. Pediatr Radiol. 2011;42(4):455–462.
7. Okanishi T, Ito T, Nakajima Y, et al. Parieto-occipital encephalomalacia in neonatal hyperammonemia with ornithine transcarbamylase deficiency: a case report. Brain Dev. 2010;32(7):567–570.
8. Groppman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. J Inherit Metab Dis. 2007;30(6):865–879.
9. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol. 2002;67(4):259–279.
10. Zwingmann C, Butterworth R. An update on the role of brain glutamine synthesis and its relation to cell-specific energy metabolism in the hyperammonemic brain: further studies using NMR spectroscopy. Neurochem Int. 2005;47(1–2):19–30.
11. Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab. 2010;100 Suppl 1:S3–S12.
12. Prestes CC, Sgaravatti AM, Pederzolli CD, et al. Citrulline and ammonia accumulating in citrullinemia reduces antioxidant capacity of rat brain in vitro. Metab Brain Dis. 2006;21(1):63–74.
13. Cowan FM, Pennock JM, Hanrahan JD, Manji KP, Edwards AD. Early detection of cerebral infarction and hypoxic ischemic encephalopathy in neonates using diffusion-weighted magnetic resonance imaging. Neuropediatrics. 1994;25(4):172–175.
14. McKinstry RC, Miller JH, Snyder AZ, et al. A prospective, longitudinal diffusion tensor imaging study of brain injury in newborns. Neurology. 2002;59(6):824–833.
